1. Home
  2. BLNK vs CRDF Comparison

BLNK vs CRDF Comparison

Compare BLNK & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Blink Charging Co.

BLNK

Blink Charging Co.

HOLD

Current Price

$0.60

Market Cap

113.9M

ML Signal

HOLD

Logo Cardiff Oncology Inc.

CRDF

Cardiff Oncology Inc.

HOLD

Current Price

$1.26

Market Cap

114.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BLNK
CRDF
Founded
2009
1999
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Specialties
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
113.9M
114.2M
IPO Year
2008
2012

Fundamental Metrics

Financial Performance
Metric
BLNK
CRDF
Price
$0.60
$1.26
Analyst Decision
Buy
Strong Buy
Analyst Count
4
4
Target Price
$2.33
$9.63
AVG Volume (30 Days)
2.6M
1.6M
Earning Date
05-08-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
61.22
27.37
EPS
N/A
N/A
Revenue
$126,197,000.00
$365,993.00
Revenue This Year
$5.71
N/A
Revenue Next Year
$19.65
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
49.61
52 Week Low
$0.45
$1.16
52 Week High
$2.65
$4.56

Technical Indicators

Market Signals
Indicator
BLNK
CRDF
Relative Strength Index (RSI) 30.41 38.33
Support Level $0.54 N/A
Resistance Level $0.73 $1.66
Average True Range (ATR) 0.04 0.14
MACD -0.01 -0.03
Stochastic Oscillator 3.54 20.00

Price Performance

Historical Comparison
BLNK
CRDF

About BLNK Blink Charging Co.

Blink Charging Co is an owner, operator, and provider of electric vehicle (EV) charging services. The company offers both residential and commercial EV charging equipment, enabling EV drivers to easily recharge at various location types. The company's business is the sale and distribution of electric vehicle charging equipment and its associated revenues earned from customers and/or Property Partners who use equipment connected to its network. It earns a majority of revenue from the U.S.A.

About CRDF Cardiff Oncology Inc.

Cardiff Oncology Inc is a clinical-stage biotechnology company that leverages PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies for various cancers with unmet medical needs. The company focuses on targeting tumor vulnerabilities with treatment combinations of onvansertib, its oral and selective PLK1 inhibitor, and standard-of-care (SoC) therapeutics. The firm's clinical program pipeline focuses on indications such as RAS-mutated metastatic colorectal cancer (mCRC), investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), metastatic triple negative breast cancer (mTNBC), and Chronic Myelomonocytic Leukemia (CMML). Geographically, it operates only in the United States.

Share on Social Networks: